XOMA Royalty (NASDAQ:XOMA) Upgraded to Hold at TD Cowen

TD Cowen upgraded shares of XOMA Royalty (NASDAQ:XOMA) to a hold rating in a research report sent to investors on Friday morning,Zacks.com reports.

XOMA has been the subject of a number of other reports. Leerink Partners cut their price objective on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a research note on Friday, December 12th. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Monday, February 9th. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.60.

XOMA Royalty Price Performance

Shares of NASDAQ XOMA opened at $24.01 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The firm has a fifty day moving average of $26.44 and a 200 day moving average of $31.08. The firm has a market cap of $297.24 million, a PE ratio of 32.45 and a beta of 0.86. XOMA Royalty has a one year low of $18.35 and a one year high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. As a group, research analysts predict that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the purchase, the chief executive officer owned 102,000 shares of the company’s stock, valued at $2,555,100. This trade represents a 5,000.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

Institutional Trading of XOMA Royalty

Institutional investors and hedge funds have recently bought and sold shares of the business. State of Alaska Department of Revenue purchased a new position in XOMA Royalty in the 4th quarter valued at about $27,000. Russell Investments Group Ltd. grew its stake in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in XOMA Royalty during the 2nd quarter worth $116,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.